Adenosine receptor ligands: differences with acute versus chronic treatment.
about
Structure-Bioactivity Relationships of Methylxanthines: Trying to Make Sense of All the Promises and the DrawbacksRegulation of hippocampal cannabinoid CB1 receptor actions by adenosine A1 receptors and chronic caffeine administration: implications for the effects of Δ9-tetrahydrocannabinol on spatial memoryGene dose effect reveals no Gs-coupled A2A adenosine receptor reserve in murine T-lymphocytes: studies of cells from A2A-receptor-gene-deficient miceAdenosine A1 receptor down-regulation in mothers and fetal brain after caffeine and theophylline treatments to pregnant ratsAdenosine receptors as drug targets--what are the challenges?Caffeine promotes wakefulness via dopamine signaling in Drosophila.Deletion of striatal adenosine A(2A) receptor spares latent inhibition and prepulse inhibition but impairs active avoidance learningDifferences in the effect of chronic and acute caffeine on self-administration of cocaine in mice.Adenosine and ischemic preconditioning.Activation of Trk neurotrophin receptors in the absence of neurotrophinsCaffeine attenuates lipopolysaccharide-induced neuroinflammation.Mechanisms mediating the ability of caffeine to influence MDMA ('Ecstasy')-induced hyperthermia in ratsMice lacking Melanin Concentrating Hormone 1 receptor are resistant to seizuresMethylxanthines, seizures, and excitotoxicity.Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration.Adenosine in the treatment of stroke: yes, maybe, or absolutely not?Mechanisms of the psychostimulant effects of caffeine: implications for substance use disorders.Modulation of neuroimmunity by adenosine and its receptors: metabolism to mental illnessCaffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer's and Parkinson's diseases.Caffeine: neuroprotective functions in cognition and Alzheimer's disease.A2A adenosine receptor protects tumors from antitumor T cells.Synthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives as adenosine receptor antagonists: A preliminary inspection of ligand-receptor recognition processStudy of A(2A) adenosine receptor gene deficient mice reveals that adenosine analogue CGS 21680 possesses no A(2A) receptor-unrelated lymphotoxicity.Caffeine prevents acute mortality after TBI in rats without increased morbidity.Adenosine and epilepsy: from therapeutic rationale to new therapeutic strategies.Working memory and the homeostatic control of brain adenosine by adenosine kinaseThe role of ATP and adenosine in the brain under normoxic and ischemic conditionsPurine receptors: GPCR structure and agonist designProtection against ischemic damage by adenosine amine congener, a potent and selective adenosine A1 receptor agonist.Postischemic administration of adenosine amine congener (ADAC): analysis of recovery in gerbilsThe adenosine kinase hypothesis of epileptogenesisSynthesis and biological evaluation of a new series of 1,2,4-triazolo[1,5-a]-1,3,5-triazines as human A(2A) adenosine receptor antagonists with improved water solubility.Increases in cerebrospinal fluid caffeine concentration are associated with favorable outcome after severe traumatic brain injury in humansNew paradigms in GPCR drug discovery.Adenosine kinase is a new therapeutic target to prevent ischemic neuronal death.The effects of caffeine on sleep in Drosophila require PKA activity, but not the adenosine receptor.Caffeine and the control of cerebral hemodynamics.Associations between food and beverage groups and major diet-related chronic diseases: an exhaustive review of pooled/meta-analyses and systematic reviews.Acute and chronic caffeine administration differentially alters striatal gene expression in wild-type and adenosine A(2A) receptor-deficient mice.Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.
P2860
Q26740559-977399EB-9A72-41A2-BAD2-F0C8A5CDEAC9Q28295045-02CE3450-EB7E-44B1-ABE6-FDB6AB31D456Q28348047-9DD4F473-AAA4-479E-AAA3-E8DE734319A2Q28582260-DDA707E3-4C2F-4BDF-988F-B8E9B62AD186Q29346491-5C247CA4-8949-427C-A9A7-7F26D10B5412Q30277361-8918ED34-1ECE-401D-B53E-3F66A4EF663CQ30440698-1B0C4994-68EA-4597-8810-9579E02A8D3AQ31437330-ED50531B-16A8-4F2D-A6EB-E283308507CCQ33801903-F268B50D-2B32-4B0B-ACCA-C9AAA91BAF73Q33937877-D18B40B4-4814-42CF-B0CE-9920AF1CF813Q34002675-9152A85D-ABD6-413D-96F2-E0185E452406Q34112855-0B3078FE-AA29-4A5E-9F98-661A1B65CEDCQ34143357-717D118D-2F42-4E04-9898-9214CED5BF6AQ34154555-1D7F3F23-62B2-4133-B2E8-AAFA618A9FE6Q34191271-B851B841-2DEC-48A7-9ACB-C10423B814FAQ34204326-D01D7F52-BB73-4BCD-93A6-92BE6189398CQ34509861-75CA47B5-1968-49E5-B200-2336E9DCEE82Q34615473-837D18C2-A194-4E72-9064-8921D29E0047Q34905120-A933AA4C-122B-49B6-9BB4-1E5F676DDB03Q34948869-AF1AD32E-4F16-421D-BE1E-C464D6180021Q35016529-CF4C06F2-B7E4-4B4D-A17F-6500D62A0D7BQ35020369-AA6CB45A-2C12-4F69-9C63-7831FDDECF0BQ35042656-C027D45E-8B5A-4D88-9181-B47CDC705529Q35803244-ECF2D558-E8A9-4436-854E-A38DCEE8A227Q35999731-2673420D-F9F1-4DB3-9D3F-C9BBC060EE9CQ36007799-3A5BACC1-82DA-446D-9CA7-2A0450A42E79Q36131077-34960D68-35A3-4021-BF50-28B5203D57D1Q36161738-7F73E898-725B-4B10-B737-08FBAF047DFCQ36225561-E3CA6004-E491-4326-B0BE-F78CA0979DA8Q36253704-0AF0C89D-D893-44BC-85E9-8D1CAFD38ABCQ36515651-0DD89FF4-766F-4BE2-83BB-989ADAB2EF3FQ36626953-7BB38752-4841-415E-9FD2-35AF97853CEEQ37022293-048F7E4C-C878-40AC-A0E5-41C2441A01CAQ37140411-74522E83-C7AF-4AEC-8412-DC62169A0D11Q37206467-28CD54EE-7B0F-4D28-AFA0-5D4C54AD5950Q37375599-6943F742-506F-4D41-8CBF-6F67260EC9CDQ37698068-46862A63-2267-4B18-A3AC-17F366ECD4F7Q38269253-C150BBF8-8660-46FE-9842-5BECF7969AEBQ38296466-275EA699-8E18-4D9A-8EDE-BB4C3DB05B14Q38584194-C86480D5-6DF1-4B4A-90DF-ECC8FDC34B8F
P2860
Adenosine receptor ligands: differences with acute versus chronic treatment.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Adenosine receptor ligands: differences with acute versus chronic treatment.
@ast
Adenosine receptor ligands: differences with acute versus chronic treatment.
@en
type
label
Adenosine receptor ligands: differences with acute versus chronic treatment.
@ast
Adenosine receptor ligands: differences with acute versus chronic treatment.
@en
prefLabel
Adenosine receptor ligands: differences with acute versus chronic treatment.
@ast
Adenosine receptor ligands: differences with acute versus chronic treatment.
@en
P2093
P2860
P1476
Adenosine receptor ligands: differences with acute versus chronic treatment.
@en
P2093
B B Fredholm
D K von Lubitz
K A Jacobson
P2860
P304
P356
10.1016/0165-6147(96)10002-X
P577
1996-03-01T00:00:00Z